1-8 of 8
Saad Z. Usmani, MD, MBA
Close
Sort by
Articles

The Year of the Bispecific

Saad Z. Usmani, MD, MBA
Journal: The Hematologist
The Hematologist (2024) 21 (1)
https://doi.org/10.1182/hem.V21.1.202415
Published: 2024
Articles

Pirtobrutinib: The Next Generation of Bruton Tyrosine Kinase Inhibitor for Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Prioty Islam, MD, Saad Z. Usmani, MD, MBA
Journal: The Hematologist
The Hematologist (2023) 20 (6)
https://doi.org/10.1182/hem.V20.6.202367
Published: 2023
Articles

Go-CART4: Cilta-cel Seeks Pole Position in Early-relapsing Multiple Myeloma

Eric Jurgens, MD, Saad Z. Usmani, MD, MBA
Journal: The Hematologist
The Hematologist (2023) 20 (5)
https://doi.org/10.1182/hem.V20.5.202358
Published: 2023
Articles

Good KarMMa Continues for CAR T-Cell Therapy in Earlier Lines of Therapy for Relapsed Refractory Multiple Myeloma

Hamza Hashmi, MD, Saad Z. Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2023) 20 (4)
https://doi.org/10.1182/hem.V20.4.2023413
Published: 2023
Articles

Smoldering Multiple Myeloma: Data on Prevalence at Last

Malin Hultcrantz, MD, PhD, Saad Z. Usmani, MD, MBA
Journal: The Hematologist
The Hematologist (2023) 20 (3)
https://doi.org/10.1182/hem.V20.3.202336
Published: 2023
Articles

Daratumumab, Lenalidomide, and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Carlyn Tan, MD, Saad Z. Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2023) 20 (2)
https://doi.org/10.1182/hem.V20.2.202329
Published: 2023
Articles

Two to Tango: CD3/BCMA Bispecific Antibodies in Multiple Myeloma

Sham Mailankody, MBBS, Saad Z. Usmani, MD, MBA
Journal: The Hematologist
The Hematologist (2022) 19 (6)
https://doi.org/10.1182/hem.V19.6.202261
Published: 2022
Articles

High-Dose Melphalan Is the Tom Brady of the Myeloma World

Binod Dhakal, MD, Saad Z. Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2022) 19 (5)
https://doi.org/10.1182/hem.V19.5.202251
Published: 2022